Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells

A preparation of autologous T lymphocytes transduced with the gamma retroviral vector MSGV1 expressing a chimeric T-cell antigen receptor (CAR) consisting of a single-chain variable fragment (scFv) from a specific antibody clone (mAb139) that targets a mutant form of epidermal growth factor receptor (EGFR) known as variant III (EGFRvIII; EGFR-vIII), with potential antineoplastic activity. Upon intratumoral administration, the gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells specifically target and bind to tumor cells expressing EGFRvIII, leading to selective cytotoxicity in EGFRvIII-expressing tumor cells. EGFRvIII, a tumor-associated antigen (TAA) encoded by an in-frame deletion of exons 2-7 in the EGFR gene, is specifically overexpressed by a subset of tumor cells and is not expressed in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and radio- and chemoresistance.
Synonym:gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified autologous T lymphocytes
MSGv1-EGFRvIII-CAR autologous T cells
MSGV1-EGFRvIII-specific CAR-transduced autologous T lymphocytes
Search NCI's Drug Dictionary